Purpose To examine the potential high throughput capability and eYciency of an automated DNA extraction system in combination with mass spectrometry for the noninvasive determination of the foetal Rhesus D status. Methods A total of 178 maternal plasma samples from RHD-negative pregnant women were examined, from which DNA was extracted using the automated Roche MagNA Pure™ system. Presence of the foetal RHD gene was detected by PCR for RHD exon 7 and subsequent analysis using the Sequenom MassArray™ mass spectrometric system. Results We determined that as little as 15 pg of RHD-positive genomic DNA could be detected in a background of 585 pg of RHD-negative genomic DNA. The analysis of the clinical samples yielded a sensitivity and speciWcity of 96.1 and 96.1%, respectively. Conclusion Our study indicated that automated DNA extraction in combination with mass spectrometry permits the determination of foetal Rhesus D genotype with an accuracy comparable to the current approaches using realtime PCR.
Introduction
The non-invasive determination of the foetal RHD status via the analysis of cell-free foetal DNA in maternal plasma or serum by real-time PCR is well established and already oVered as a clinical service in a number of countries [2, 6] . This development can greatly assist with the screening and monitoring of pregnancies at risk for haemolytic disease of the foetus and newborn (HDN), and also reduce the health care costs by avoiding unnecessary prophylactic treatment in those cases where the foetus is RHD negative [7] .
It has recently been shown that MALDI-TOF (matrix assisted laser desorption ionization-time of Xight) mass spectrometric devices, such as the Sequenom MassArray™ system, can be used for the detection of foetal genetic loci by the analysis of cell-free foetal DNA in maternal plasma or serum [11, 12] . The main advantage of this approach over conventional real-time PCR is that it permits the ready detection of foetal genetic loci which only diVer slightly from the maternal counterpart, such as point mutations. Furthermore, it is possible to examine a large number of multiplex PCR products by mass spectrometry, implying that a large number of mutations or diVerent loci can be examined in a single analysis [18] . A further attribute of the MassArray™ system is that it is highly amenable to high throughput analysis of several thousand samples per day. Consequently, it has been proposed that this system may be suitable for the analysis of cell-free foetal DNA in routine clinical diagnostic labs [5, 11, 12] .
As to date few large-scale studies have examined the suitability of such a system for this purpose, we have now performed a study in which 178 clinical samples were analysed in a blinded manner for the presence or absence of the foetal RHD gene.
Materials and methods

Plasma sample collection and processing
The study was approved by the review boards from both the institutions. After written informed consent, 15 mL EDTA blood samples were obtained from pregnant women at risk for HDN caused by alloimmunization. The samples were processed on site at the University of Göttingen, Germany, by twofold centrifugation (1: 10 min, 2,700£g; 2: 45 min 12,500£g). The plasma was divided into 1 mL aliquots and stored at ¡80°C. One aliquot of each sample was frozen and sent to Basel for analysis.
DNA isolation from maternal plasma
The automatic DNA isolation system MagNA Pure™ instrument (Roche Applied Science, Switzerland) was used for plasma DNA extraction. Following the "DNA LV Blood_1000.blk" protocol, DNA was extracted from 1 mL of RHD-negative maternal plasma with the Roche MagNA Pure™ Pure LC DNA Isolation Kit-Large Volume. The DNA was eluted into 200 L of elution buVer and stored at ¡20°C for later use. A sample volume of 50 L was available for analysis.
Assay design
The assay design was kindly provided by Sequenom Inc., USA. As only the foetal RHD gene is detected, and no corresponding maternal allele, a SABER (single allele base extension reaction) assay was used which exclusively detects the presence of the RHD 7 exon (see below). All oligonucleotides were synthesised and HPLC puriWed by Microsynth (Switzerland). AmpliWcation primers contained a 5Ј-10 mer tag to keep them out of the analytical mass range.
PCR ampliWcation
PCR reactions were performed in a total volume of 12.5 L containing 8 L of eluted cfDNA, 400 nM of each primer (PCR-RHD7-fw and PCR-RHD7-rev, Table 1 ), 3 mM Mg 2+ , 0.5 U HotStart Taq DNA Polymerase (Qiagen, Switzerland), 50 M dNTPs and 1£ PCR buVer. Thermal cycling was performed as follows: 15 min at 95°C followed by 50 cycles of 95°C for 45 s, 57°C for 45 s and 72°C for 1 min. The reaction was completed with a Wnal extension at 72°C for 7 min.
Shrimp alkaline phosphatase (SAP) treatment
For the dephosphorylation of excess dNTPs, 4 L of a solution containing 3.06 L ddH 2 O, 0.34 L hME buVer (Sequenom Inc.) and 0.6 L shrimp alkaline phosphatase (Sequenom Inc.) were added to 12.5 L of PCR product. After incubation at 37°C for 60 min, the enzyme was inactivated at 85°C for 5 min. (Table 1 ) and 0.08 L (2.56 U) Thermo Sequenase (Sequenom Inc.) were added to 18.5 L SAP treated PCR product. Thermal cycling was performed as follows: 2 min at 94°C followed by 99 cycles of 94°C for 5 s, 51°C for 5 s and 52°C for 5 s.
Desalting and mass spectrometric analysis A total of 29.5 L H 2 O and 6 mg of SpectroCLEAN resin (Sequenom Inc.) were added to 20.5 L extension product. The plate was rotated for 10 min at room temperature followed by centrifugation at 3,000£g for 3 min to pellet the resin.
A total of 15 nL of each desalted sample were dispensed onto a 384-format SpectroCHIP using a MassARRAY 
Results
Validation of the mass spectrometry Assay for RHD exon 7
To evaluate the sensitivity of the SABER assay, we serially diluted RHD-positive genomic DNA into RHD-negative genomic DNA, such that the overall quantity of DNA was 600 pg per reaction. This is the equivalent amount to that normally present in cell-free DNA preparations. Under these conditions, we were able to detect 15 pg of RHD-positive genomic DNA in a background of 585 pg of RHD-negative genomic DNA (Fig. 1) . This is almost equal to the three copies of the RHD gene in a single reaction, indicating that the RHD assay exhibits a degree of sensitivity and speciWcity suitable for the analysis of cell-free foetal DNA.
Detection of the foetal RHD exon 7 in maternal plasma
A total of 178 samples were analysed in a blinded manner. The results were conWrmed by those obtained from serological analysis using cord blood in Göttingen. The presence or absence of the foetal RHD exon 7 was determined following the analysis of the samples in duplicates. If the result was unambiguously positive or negative, the samples were scored accordingly. If the result was equivocal, the sample was re-analysed in duplicate. The sample was only Following a comparison of our results with those obtained by classical serology of the cord blood, we ascertained that out of 178 samples we had examined, Wve samples had been incorrectly scored as RHD negative and two samples incorrectly determined as being RHD positive ( Table 2) . This equates to a sensitivity of 96.1% and a speciWcity of 96.1%. Our data show 96.1% concordance to those obtained by quantitative real-time PCR.
Discussion
Non-invasive prenatal RHD analysis is currently most frequently performed using real-time PCR, either in conjunction with manual or automated procedures for the extraction of cell-free DNA from the maternal plasma/ serum samples [4, 9, 13, 15, 16, 19] . In this study, we analysed the foetal RHD status by mass spectrometry, in combination with automated system for the extraction of cell-free DNA from maternal plasma.
The validation of the assay showed that we were able to detect as little as 2.5% of RHD-positive genomic DNA in a background of RHD-negative genomic DNA, indicating that the assay is very sensitive. A similar sensitivity (20 pg mutant DNA in 580 pg wildtype DNA) has recently been reported by our group for the mass spectrometry based genotyping of the foetal KEL1 blood group from cell-free DNA in maternal plasma [11] .
Out of 178 samples, Wve cases were incorrectly scored as RHD negative and two were incorrectly scored as RHD positive. Of those Wve false negative samples, three were obtained during the third trimester, while the remaining two were from the second trimester of pregnancy. The two samples that were scored false positive were from the second and third trimester or pregnancy. These remained to be assessed incorrectly, even after several rounds of re-analysis, indicating that the sample may have been contaminated. As the samples stem from a Caucasian population, a false positive result caused by the inactive allele RHD [10, 16] is unlikely, but can only be excluded convincingly by examining for the presence of this allele.
In those cases where the foetal RHD gene cannot be detected, it is unclear, whether the foetus is Rhesus-negative or if the amount of foetal DNA in the sample is below the detection limit of the system. For the exclusion of the latter case, the detection of paternally inherited single nucleotide polymorphisms [12] , the detection of a Y-chromosome speciWc sequence [8] , or the detection of an epigenetic marker such as the foetal hypermethylated RASSF1A sequence [3] can be performed. In our current study, we were unable to perform such additional analyses due to very limited amount of sample available.
A recent review of large-scale studies reporting on the non-invasive determination of foetal RHD status by the real-time PCR analysis of cell-free DNA indicated that accuracies between 95 and 99% could be attained [14] . As such, our data yielding an overall accuracy of 96.1% concur favourably with those obtained by real-time PCR.
In future studies we aim to make better use of the Sequenom MassArray™ mass spectrometric system, by performing multiplex analyses. In this manner it will be possible to detect variant RHD alleles such as the RHD gene [1, 17] , as well as polymorphic markers indicating whether cellfree foetal DNA was present in the sample or not. This added information will increase the value of the analysis, and by being able to perform these numerous examinations in a single analytic run, help to reduce costs.
In this manner, the combination of an automated DNA extraction system and mass spectrometry may emerge as a competitive alternative to the current commonly used realtime PCR approaches used to determine non-invasively the foetal RHD status. 
